Home

CLL Guidelines NCCN

The NCCN Guidelines for Patients sheets are available to read and download for free online and via the NCCN Patient Guides for Cancer mobile app. Printed editions can be ordered from Amazon.com for a small fee. NCCN Guidelines for Patients DO NOT replace the expertise and clinical judgment of the clinician NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019 Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course Overview. Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) constitutes approximately 7% of newly diagnosed cases of non-Hodgkin's lymphoma. 1 CLL remains the most prevalent adult leukemia in Western countries. In 2018, an estimated 20,940 people were diagnosed with CLL and an estimated 4,510 people died of the disease in the United States. 2 CLL is generally characterized by. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues

Chronic Lymphocytic Leukemia - Find NCCN Guidelines For CL

  1. nccn makes no representations or warranties concerning the nccn content, the nccn guidelines or derivative resources provided by nccn, all of which are provided as is. NCCN DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE
  2. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL. Overview Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues
  3. Updates in Version 2.2019 of the NCCN Guidelines for CLL/SLL from Version 1.2019 include: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma CSLL-C 2 of 4 • Tumor lysis syndrome Bullet was removed, Consider TLS prophylaxis for patients at high risk for TLS, including those with bulky disease and those with progressive disease.

Chronic Lymphocytic Leukemia - NCC

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017 Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way Cohort Study of CLL and Leukemia Cutis From the French Innovative Leukemia Organization. By: Lauren Harrison, MS Posted: Wednesday, July 28, 2021. The presence of leukemia cutis among a cohort of patients with chronic lymphocytic leukemia (CLL) did not appear to have an impact on prognosis, and no specific clinical or biologic profile was found to be associated with leukemia cutis, according.

Core Strategies in CLL to Mitigate Risks & Optimize Patient-Centered Care. CAR-T Cell Therapy for Blood Cancer Patients. Chronic Lymphocytic Leukemia Update, Issue 1, 2019. IGHV-Unmutated CLL: Gene Signature May Predict Outcomes After First-Line FCR. View More These updated ESMO Clinical Practice Guidelines provide key recommendations on the management of chronic lymphocytic leukaemia (CLL) Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe Recommendations are provided, including levels of evidence and grades of recommendation where applicabl

Chronic Lymphocytic Leukemia Approaches to Individualized Treatment for Chronic Lymphocytic Leukemia: Expert Guidance on Sequencing Therapy, Novel Agents, and their Combinations The goal of this program is to improve the knowledge and competence of clinicians to implement best practices in the treatment of CLL The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma have been updated to reflect these changes NCCN Guidelines Include Obinutuzumab in CLL. Amid advances in targeted therapies for patients with chronic lymphocytic leukemia (CLL), researchers also have been making strides in the realm of chemoimmunotherapy regimens for the disease. This illustration depicts the obinutuzumab antibody binding to the CD20 antigen on the B-cell surface

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC Target Audience This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with CLL/SLL NCCN Treatment Guideline Updates for Chronic Lymphocytic Leukemia. April 9, 2019. Conference | HOPA Ahead. Updated clinical practice guidelines from the National Comprehensive Cancer Network (NCCN) review patient selection for the use of agents such as ibrutinib for the treatment of chronic lymphocytic leukemia. YouTube. Specialty Pharmacy Times

Updates in Version 2.2018 of the NCCN Guidelines for CLL/SLL from Version 1.2018 include: NCCN Guidelines Version 3.2018 Updates. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. CSLL-D • The NCCN Categories of Preference has been applied to the suggested treatment regimens National Comprehensive Cancer Network (NCCN) recommends Brukinsa for chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL). The December 2020 NCCN guidelines recommended Brukinsa (zanubrutinib) as a first-and second-line treatment for CLL/SLL. This is noteworthy partly because Brukinsa is approved for mantle cell lymphoma, not for CLL/SLL.The NCCN recommendations were based on. The NCCN is an alliance of 21 leading cancer centers. The NCCN has developed treatment guidelines for most types of cancer, including NHL and leukemia, and updates their guidelines annually. This year, the chemotherapy agent Treanda was added to updated guidelines including follicular NHL, mantle-cell NHL, and CLL

The National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines for the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) On the NCCN [National Comprehensive Cancer Network] Guidelines, we have 2 options. One is ibrutinib as a category 1 and the other is acalabrutinib as a category 1

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN . Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CSLL-1 Follicular Lymphoma (FOLL-1 The National Comprehensive Cancer Network (NCCN ) makes n In 2008, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) published consensus guidelines for the design and conduct of clinical trials for patients with CLL that were revised from those previously published by the National Cancer Institute-sponsored Working Group. 1-3 Those guidelines provided definitions intended to standardize the assessment of patients that were adopted. EP. 8: BCL2 Inhibitor in Combination With Anti-CD20 mAb for CLL. Kirollos S. Hanna, PharmD, BCPS, BCOP: With all these combinations, it seems like the data with BTK [Bruton tyrosine kinase] combining with an anti-CD20 are somewhat iffy right now, and that's why it's usually a plus or minus. Now, transitioning and going to the BCL2.

NCCN guidelines recommend CpG-stimulated metaphase karyotype for the identification of complex karyotype, which is characterized by the presence of at least 3 independent chromosomal abnormalities. Venetoclax (Venclexta), an inhibitor of BCL2, an antiapoptotic protein overexpressed in CLL, 4 is one of those novel oral agents. It is currently approved for the treatment of adult patients with CLL or SLL. 5 According to the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), venetoclax plus obinutuzumab is a preferred first. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN , 18 (2), 185-217 Zanubrutinib for Resistant CLL and Small Lymphocytic Lymphoma. By: Julia Fiederlein Posted: Friday, July 24, 2020. In a multicenter phase II study, zanubrutinib seemed to achieve high overall response rates in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to Jianyong Li, MD, PhD, of The First Affiliated Hospital of.

The full NCCN Guidelines for CML (available at NCCN.org) discuss the clinical management of CML in all 3 phases (chronic, accelerated, or blast phase). Evaluation for diseases other than CML as outlined in the NCCN Guidelines for MPN is recommended for all patients with BCR-ABL1-negative MPN. The diagnosis and management of CP-CML is included. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/ SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL. Original language: English: Pages (from-to) 293-311 A wonderful walk through CLL and with acknowledgement of the emotional challenges. Great questions and room to make notes. In the UK currently, there is a big collaboration going on between the top UK CLL experts, including Anna Schuh and Peter Hillman (+others) to get some new CLL treatment guidelines finished for later this year/early next.

NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/ SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL. J Natl Compr Canc Netw 2017;15(3):293-311 The National Comprehensive Cancer Network (NCCN) added tafasitamab-cxix to its latest Clinical Practice Guidelines in Oncology for the treatment of patients with B-cell lymphomas, according to a press release issued jointly by MorphoSys AG and Incyte, the drug's manufacturers.. The NCCN issued a Category 2A designation for tafasitamib — a humanized Fc-modified cytolytic CD19 targeting. Does Ibrutinib Pretreatment Reduce the Risk of Obinutuzumab-Related Infusion Reactions in CLL? By: Kayci Reyer Posted: Monday, August 2, 2021. Findings from an analysis of the phase III iLLUMINATE study, presented in the Annals of Hematology, indicate that pretreatment with ibrutinib may be able to reduce infusion-related reactions associated with obinutuzumab treatment for some patients with.

NCCN Guidelines - National Comprehensive Cancer Networ

Monday, April 26 at 1:00 pm - 2:15 pm Add to Calendar 2021-04-26 20:00:00 2021-04-26 21:15:00 NCCN Patient Webinar on Chronic Lymphocytic Leukemia The National Comprehensive Cancer Network (NCCN) presents a free webinar for people with chronic lymphocytic leukemia (CLL), their caregivers, and their families:Know What Your Doctors Know: Chronic Lymphocytic Leukemia Join experts as they discuss. TGTX earnings call for the period ending June 30, 2021. Motley Fool Transcribers. (MFTranscribers) Aug 4, 2021 at 3:20AM. Image source: The Motley Fool. TG Therapeutics, inc ( NASDAQ:TGTX) Q2 2021. The NCCN or National Comprehensive Cancer Network is a not-for-profit alliance of 26 leading international cancer institutes that puts together evidence-based guidelines to better inform treatment decisions. Here is a link to a PDF the NCCN's most current guidelines on NHL (Non-Hodgkin's Lymphomas) that include CLL, published in 2015

MCL and CLL: NCCN Guidelines and Treatment Option

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. V.2.2021. V.2.2021. National Comprehensive Cancer Network, Inc. 2020 NCCN is dedicated to improving the quality of cancer care, so patients can lead better lives. They provide cancer treatment guidelines for use by patients and healthcare providers worldwide. NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) recommends ibrutinib (IMBRUVICA®) as a preferred initial treatment for people with CLL/SLL

The Know Your CLL Check-in Summary will include a list of common CLL genetic markers and questions to ask your doctor. You know some specifics about your CLL. However, your CLL genetic characteristics aren't listed. Your Diagnosis Report includes space for you to write down your CLL genetic characteristics Recent NCCN guidelines that were updated on Dec. 3, 2020, now recommend the drug as both a first- and second-line treatment in CLL/SLL, including: - First-line therapy of Brukinsa as a single agent is recommended for the treatment of CLL/SLL with del(17p) and TP53 gene mutations in patients with a contraindication to other BTK inhibitors who. NCCN. Clinical Practice Guidelines in Oncology. Chronic lymphocytic leukemia/small lymphocytic leukemia, version 1.2021. Accessed November 18, 2020 CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATMENT REGIMENS. Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for.

Recently Updated Guidelines - NCC

  1. Chemotherapy. Chemotherapy drugs can be given in several ways: by mouth in the form of a pill, infused (put into your body through a vein), injected, or applied to the skin. This type of treatment can be taken on its own or with other treatments. It works by entering the bloodstream to stop or slow the growth of CLL cells throughout the body. 1,3
  2. Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. Th
  3. The risk assessment is notable for high-risk features of a diagnosis of CLL, high lymphocyte count, extensive lymphadenopathy, splenomegaly, progression on small molecule inhibitor therapy, and planned chemoimmunotherapy, per NCCN Guidelines (2020a). He has favorable findings of normal serum creatinine, phosphate, potassium, and uric acid

The updated NCCN guidelines for chronic lymphocytic leukemia (CLL) take the treatment of the disease further into the age of targeted therapies by upgrading recommendations for the use of ibrutinib Jacqueline Barrientos, MD, MS, Feinstein Institute for Medical Research, Manhasset, NY, outlines the findings of an analysis of the real-world application of the National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology for chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) based on data from the INFORMCLL registry Chemotherapy for Chronic Lymphocytic Leukemia. Chemotherapy (chemo) uses anti-cancer drugs that are taken by mouth or injected into a vein or muscle to kill or control cancer cells. When given this way, these drugs enter the bloodstream and reach all parts of the body, so chemo is useful for cancers that tend to spread throughout the body, like.

NCCN Recommends Zanubrutinib as First-Line - CLL Societ

  1. 14. NCCN. Clinical Practice Guidelines in Oncology. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 2.2020. Accessed April 26, 2021. 15. Poonacha TK, Go RS. Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines
  2. Obinutuzumab Gains Role in CLL Guidelines. March 25, 2014. Anita T. Shaffer. OncologyLive, March 2014, Volume 15, Issue 3. Amid advances in targeted therapies for patients with chronic lymphocytic.
  3. NCCN Categories of Evidence and Consensus 1. Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. NCCN Categories of Preference 1. Preferred intervention: Interventions that are based on superior efficacy, safety, and.
  4. New NCCN Guidelines Inform MCL Decision-Making. The National Comprehensive Cancer Network (NCCN) has published updated patient guidelines for mantle cell lymphoma (MCL).The NCCN Guidelines for Patients® are based on the clinical practice guidelines for physicians but are written in an easy-to-understand format for patients and care partners. The guidelines provide a step-by-step guide of.
  5. Talk to your doctor to see if achieving uMRD may be a goal of your CLL treatment plan. Before treatment. With untreated CLL, cancerous B cells are present in the body. 13. With treatment: detectable MRD. For some people who receive CLL treatment, cancerous B cells may be lessened but still detectable in the body. 13
  6. For this analysis, NCCN Guidelines ® for CLL/SLL V.2.2017 were used given 74 percent enrollment in 2017. 3. The latest analysis showed that a third of high-risk patients with 17p deletion/TP53 mutation, who typically have poor outcomes after chemoimmunotherapy (CIT),.

NCCN: Cancer and COVID-19 Vaccination CLL Societ

Targeted Therapies in Oncology, December 2018, Volume 7, Issue 12. Recent FDA drug approvals in hematologic malignancies have changed the treatment paradigm of many diseases and resulted in necessary updates to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Meletios A. Dimopoulos, MD Chronic lymphocytic leukemia (CLL) is a type of cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made. The term chronic in chronic lymphocytic leukemia comes from the fact that it typically progresses more slowly than other types of leukemia ZYDELIG is indicated for relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities. Idelalisib (ZYDELIG) + rituximab is a PREFERRED treatment option in the NCCN Guidelines ® for appropriate patients with relapsed/refractory. NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) and NCCN Drugs & Biologics Compendium (NCCN Compendium ®) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).These NCCN Guidelines ® are currently available as Version 1.2017. · The NCCN Guidelines for CLL/SLL (previously included as part of NCCN Guidelines for Non. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. Journal Article (Journal Article) Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid.

NCCN Guidelines® IMBRUVICA® (ibrutinib) for CL

NCCN Guidelines: Rapid Change in CLL Treatment Concept

• For the current analysis, the NCCN Guidelines for CLL/SLL V.2.2017 were chosen, given 74% of patients were enrolled in informCLL in 2017 or later. — NCCN Guidelines for CLL/SLL V.2.2017 provided treatment recommendations by lne oi f therapy (LOT) and del(17p)/ TP53. mutatoi n status; for pateni ts wtihout . del(17p)/ TP5 NCCN Guidelines for Treatment-Naive CLL 2020 - CLL Support. CLL Support. 17,831 members • 29,182 posts. Join Write. Home; About; Posts; Members; NCCN Guidelines for Treatment-Naive CLL 2020. relapsed CLL. More here but unfortunately the full paper is behind a paywall:..

JNCCN 360 - CLL - Cohort Study of CLL and Leukemia Cutis

The NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN .® ® NCCN Guidelines Index NHL Table of Contents Discussion Continue NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines )® Non-Hodgkin's Lymphomas NCCN.org Version 2.201 Abstract: EP635 Type: E-Poster Presentation Session title: Chronic lymphocytic leukemia and related disorders - Clinical Background NCCN Guidelines ® provide recommendations on evolving standards of care to inform treatment (tx) decisions.. Aims To understand the application of guidelines in routine clinical practice, we assessed how tx regimens in the informCLL registry (Mato ASH 2020.

Targeted therapies are drugs that specifically target the changes inside cells that cause them to become cancer. Unlike standard chemotherapy drugs, which work by attacking rapidly growing cells in general (including cancer cells), these drugs target one or more specific proteins on or in chronic lymphocytic leukemia (CLL) cells. When treatment is needed for CLL, a targeted drug is often part. Guidelines Th e National Comprehensive Cancer Network (NCCN) guidelines on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (version 1.2020 ± August 23, 2019) recommends Arzerra in combination with bendamustine for the first -line treatment of CLL/small lymphocytic lymphoma (SLL CLL/SLL Guidelines. v4.2020; Gentile M, et al. Haematologica. 2009. 4:17 So in looking at prognositic factors and some of the genetic abnormalities CLL is a Complex Diseas The current iteration of the NCCN guidelines for non-Hodgkin's lymphoma, which include CLL as a subcategory, highlight the evidence confirming the superiority of FCR over bendamustine plus.

Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCCN Establishes Guidelines for Treating People With HIVVerastem's Earnings: Is It a Buy Now? – MS Money MovesASH 2018: Dr

Innovations in the Treatment of Chronic Lymphocytic Leukemia - Episode 7. BTK Inhibitor in Combination With Anti-CD20 mAb for CLL NCCN Guidelines: Rapid Change in CLL Treatment Concepts. EP. 3: Therapy Great question, and as I mentioned before, the NCCN [National Comprehensive Cancer Network] guidelines interestingly stick with. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) recommend TLS prophylaxis and monitoring based on tumor burden in patients with CLL/SLL receiving venetoclax 1: Management of patients with CrCl <80 mL/min and medium tumor burden (any lymph node 5 cm to <10 cm or ALC ≥25 x 10 9 /L) as high risk for TLS NCCN publishes helpful guidelines for doctors and patients about how to best handle a particular cancer including CLL/SLL. Like many such guidelines, these are good when they are first assembled, but by the time they are published can be out of date especially with a disease such as CLL where treatment is changing so quickly

National Comprehensive Cancer Network The National Comprehensive Cancer Network ® (NCCN ® ) is an alliance of 26 of the world's leading cancer centers , working together to develop treatment guidelines for most cancers, and dedicated to research that improves the quality, effectiveness, and efficiency of cancer care These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL. Full text links . Read article for free,.

In: National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. NCCN 2019 May from NCCN website (free registration required) Eichhorst B, Robak T, Montserrat E, ESMO Guidelines Committee. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015 Sep;26 Suppl. As You ARE. Did you know that everyone's experience with chronic lymphocytic leukemia (CLL) is unique? There are tests that your doctor can use to help determine your CLL's features. These features, your medical history, and physical health are some factors that can inform how your CLL may progress and what treatments you and your doctor might. National Comprehensive Cancer Network ® (NCCN ®) NCCN Guidelines ® recommend (Category 2A) the use of bendamustine in the treatment of CLL 2 † ORR was defined as complete response + nodular partial response + partial response Certain signs and symptoms might suggest that a person has chronic lymphocytic leukemia (CLL), but tests are needed to be sure. Medical history and physical exam If you might have leukemia, your doctor will want to take a complete medical history to check for symptoms and possible risk factors

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation inDiagnose: Diagnosing LeukemiaStrategies for Optimal Management of High-Risk CLL

Zanubrutinib has previously showed promising results in patients with relapsed/refractory CLL in a phase 2 trial (NCT03206981). In this population, an ORR of 87.9% per the IRC was observed in a total cohort of 91 patients, with 6.6% achieving complete response and 69.2% achieving a partial response. We are pleased to see that at the interim. Clinical guidelines may help to standardize clinical prac-tice and timing of palliative care referral. Widely adopted nationally and internationally, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncol-ogy have a critical role to facilitate knowledge translation and may guide insurance reimbursement [12] Jacqueline Barrientos, MD, MS, Feinstein Institute for Medical Research, Manhasset, NY, outlines the findings of an analysis of the real-world application of.. The Leukemia and Lymphoma Society. Chronic Lymphocytic Leukemia. White Plains, NY: The Leukemia and Lymphoma Society; 2014. Publication No. PS34 40M. Shanafelt T, Bowen D, Venkat C, et al. The physician-patient relationship and quality of life: lessons for chronic lymphocytic leukemia. Leuk Res. 2009;33(2):263-270. American Cancer Society